Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | June 20, 2025 | June 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 20, 2025 · Filed June 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,258 |
Reported balance
After 2025-06-20 transaction · row 1
1 source rowRow 1 · 2025-06-20 · Grant · Acquired 14,164 · Balance 50,258 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2025 Filed Jun 24, 2025 21:13 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 14,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-004070 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,258 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 5,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-003908 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,094 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-003960 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,323 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 7,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-004300 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,823 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2023 annual meeting of the Company's stockholders or June 8, 2023. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004428 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,869 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001360 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,697 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 4,355 | $57.21 | $249,149.55 |
DisclosureSEC source: 0001171843-19-005733 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 F1 · price: Represents the weighted average sales price. The shares were sold on 8/28/19 at prices ranging from $57.14 to $57.34 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:35 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001390 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,945 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000694 · formfour.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,103 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:09 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000589 · formfour.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,477 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.